RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Six Months ended September 30, 2017
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets prescription and over-the-counter finished pharmaceutical products, active pharmaceutical ingredients (APIs), and differentiated formulations globally.

Key Financial Metrics

All figures in Indian Rupees (Rs.) millions unless otherwise noted. Convenience translation to U.S. dollars provided at Rs. 65.30 = $1.00.

Income Statement Highlights (Six Months Ended Sept 30, 2017)

Balance Sheet Highlights (As of Sept 30, 2017)

Cash Flow (Six Months Ended Sept 30, 2017)

• Operating Cash Flow: Rs. 4,728M ($72M) inflow (Decreased from Rs. 7,763M in prior year due to working capital increases and lower earnings).
• Investing Cash Flow: Rs. 5,456M ($84M) outflow (Significant decrease in outflow compared to prior year due to reduced M&A activity).
• Financing Cash Flow: Rs. 646M ($10M) outflow (Driven by repayment of short-term borrowings and dividends).

Material Changes vs. Prior Period

• Revenue Stability: Consolidated revenues remained flat (+1% for six months, -1% for the quarter) despite currency fluctuations. Growth in Emerging Markets (Russia +33% for six months) and Europe (+33% for six months) offset declines in North America (-8% for six months) and India (-4% for six months).
• Margin Compression: Gross margins declined to 52.5% (from 56.1% prior year) primarily due to price erosion in North America and PSAI segments, and a shift in product mix toward lower-margin products.
• Profit Decline: Net profit decreased 18% year-over-year. This was driven by lower gross margins, reduced finance income (due to lower profits on sale of investments), and higher tax rates (26% vs 24% prior year).
• Debt Structure: Long-term borrowings increased significantly (from Rs. 5,449M to Rs. 24,952M) as the company refinanced short-term debt used for the Teva ANDA acquisition into long-term facilities in Switzerland and Germany.
• Working Capital: Days Sales Outstanding (DSO) increased to 109 days (from 96 days) due to changes in customer mix and higher exchange rates impacting receivables valuation.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary & Outlook

• Product Launches: The company launched 4 new products in North America and 8 in India during the quarter. The pipeline includes complex generics, biosimilars, and differentiated products.
• Regulatory Progress: The U.S. FDA closed the inspection of the Miryalaguda API facility in June 2017. However, the company continues to address observations at other facilities (Srikakulam, Duvvada, Mirfield).
• Collaborations: Completed the acquisition of Merck KGaA's biosimilars business by Fresenius Kabi; the collaboration with DRL continues with Fresenius Kabi. Entered new out-licensing agreements with CHD Biosciences and Encore Dermatology.

Risks and Contingencies

• Regulatory Actions:
  • India (NPPA): Ongoing litigation regarding price controls on cardiovascular and anti-diabetic formulations. The company has deposited Rs. 100M and provided a bank guarantee of Rs. 676M pending a hearing.
  • U.S. FDA: Warning letter from 2015 regarding cGMP deviations at three Indian facilities. While one facility inspection is closed, others remain under review. Non-compliance could lead to import bans or withholding of new product approvals.
  • Germany: GMP compliance certificate for the Bachupally facility was not renewed by Bavarian authorities, halting exports to the EU until resolved.
• Legal Litigation:
  • Antitrust: Named as a defendant in a multi-district litigation (MDL-2724) involving 45 U.S. states alleging price-fixing and bid allocation for generic drugs (zoledronic acid and meprobamate).
  • False Claims Act: Plaintiffs refiled an amended complaint regarding child-resistant packaging; the company is seeking dismissal.
  • Patent/Commercial: Various disputes including Nexium, Namenda, and Mezzion litigation. The company believes liability is not probable for most.
• Venezuela Operations: Continued currency devaluation and exchange controls have resulted in foreign exchange losses. No revenues were earned from Venezuela in the current period.

Key Facts for Investor Verification

• North America Price Erosion: Verify the extent of price erosion in the U.S. generics market and its impact on future gross margins, as this was a primary driver of profit decline.
• Regulatory Resolution: Monitor the status of the U.S. FDA re-inspections and the German GMP certification renewal, as these directly impact the ability to export products from key facilities.
• Debt Refinancing: Confirm the terms and interest rate exposure of the new long-term borrowings (USD and EUR) that replaced the short-term Teva acquisition debt.
• Working Capital Trends: Track the Days Sales Outstanding (DSO) metric, which has risen to 109 days, to assess potential cash flow constraints.
• Legal Exposure: Review the status of the State Attorneys General antitrust action (MDL-2724) and the NPPA price control litigation in India for potential financial provisions.